Fig. 4: T cell responses against SARS-CoV-2.

a T cell responses to selected SARS-CoV-2 antigens in the patient on day 127 after diagnosis and in five convalescent donors (HD1–5) after mild infection were tested in ex vivo IFN-γ ELISPOT using overlapping peptide pools spanning selected SARS-CoV-2 antigens as indicated (lineage Wuhan-Hu-1). Tests were performed in three technical replicates. Mean values with standard deviation are shown. b Expression of activation markers CD38 and HLA-DR on the patient’s peripheral CD8 or CD4 T cells were analyzed on day 145 by flow cytometry. Source data are provided in the Source Data file.